Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE
2023-508812-45-00Phase 3Completed
- Sponsor
- Biohaven Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in Idiopathic generalized tonic-clonic epilepsy (IGTCE) comparing BHV-7000 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Time to the second day with a GTC seizure during the double-blind phase. Started Oct 2024; status: completed.
02
Drugs
opakalim
03
Conditions
Idiopathic generalized tonic-clonic epilepsy (IGTCE)
Beyond the preview
Go deeper on 2023-508812-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508812-45-00.